Boston Pharma 
Welcome,         Profile    Billing    Logout  
 0 Products   0 Diseases  0 Products   0 Trials   0 News 
7 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BOS-342 / Boston Pharma
ACTRN12623000798662: A First-in-Human, Open-label, Phase 1/2 Study of BOS-342 in Patients with Hepatocellular Carcinoma (HCC) and other Glypican 3 (GPC3)-expressing Tumors

Terminated
1/2
81
 
Boston Pharmaceuticals, Inc., Boston Pharmaceuticals, Inc.
Hepatocellular Carcinoma (HCC), Other GPC3-expressing Tumors
 
 
SLX-0528 / Xenthera, Biolexis Therap
NCT05474859: Subjects With Advanced or Metastatic Solid Tumor Malignancies

Not yet recruiting
1
30
NA
XT-0528
Xenthera, Inc.
Metastatic Solid Tumor, Advanced Solid Tumor
01/28
06/28
zeteletinib (BOS-172738) / Boston Pharma
NCT03780517: Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

Completed
1
117
Europe, US, RoW
BOS172738
Boston Pharmaceuticals
Advanced Nonhaematologic Malignancies
09/23
09/23
efimosfermin alfa (BOS-580) / GSK
BOS-580-201, NCT04880031: A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

Active, not recruiting
2
231
US
Efimosfermin, BOS-580, Placebo
Boston Pharmaceuticals
Nonalcoholic Steatohepatitis (NASH)
11/25
11/25
NCT06920043: A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) MASH

Recruiting
2
42
US
Efimosfermin, BOS-580, Placebo
Boston Pharmaceuticals
Metabolic Dysfunction-Associated Steatohepatitis
11/27
11/27
AKP-11 / Akaal Pharma, Boston Pharma
ACTRN12617001223325: A Phase II Trial of Safety, Tolerability and Efficacy Study of Topical AKP-11 Administration to Participants with Arthritis.

Recruiting
2
100
 
Akaal Pharma PTY LTD, Akaal Pharma PTY LTD
arthritis treatment, osteoarthritis treatment, rheumatoid arthritis treatment, Gout treatment
 
 
ancremonam (BOS-228) / Boston Pharma
2017-003130-90: LYS228 PK, clinical response, safety and tolerability in patients with complicated intra-abdominal infection (cIAI)

Not yet recruiting
2
60
RoW, Europe
Piperacillin/tazobactam, Vancomycin (INN), Metronidazole (INN), Meropenem, LYS228, Powder for solution for infusion, Powder for concentrate for solution for infusion, Solution for infusion, Powder for solution for injection/infusion, Not specified; commercially available piperacillin/tazobactam; locally sourced, Not specified; commercially available vancomycin; locally sourced, Not specified; commercially available metronidazole; locally sourced, Not specified; commercially available meropenem; locally sourced
Novartis Pharma AG, Novartis Pharma AG
complicated Intra-Abdominal Infections (cIAI), complicated Intra-Abdominal Infections (cIAI), Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BOS-342 / Boston Pharma
ACTRN12623000798662: A First-in-Human, Open-label, Phase 1/2 Study of BOS-342 in Patients with Hepatocellular Carcinoma (HCC) and other Glypican 3 (GPC3)-expressing Tumors

Terminated
1/2
81
 
Boston Pharmaceuticals, Inc., Boston Pharmaceuticals, Inc.
Hepatocellular Carcinoma (HCC), Other GPC3-expressing Tumors
 
 
SLX-0528 / Xenthera, Biolexis Therap
NCT05474859: Subjects With Advanced or Metastatic Solid Tumor Malignancies

Not yet recruiting
1
30
NA
XT-0528
Xenthera, Inc.
Metastatic Solid Tumor, Advanced Solid Tumor
01/28
06/28
zeteletinib (BOS-172738) / Boston Pharma
NCT03780517: Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

Completed
1
117
Europe, US, RoW
BOS172738
Boston Pharmaceuticals
Advanced Nonhaematologic Malignancies
09/23
09/23
efimosfermin alfa (BOS-580) / GSK
BOS-580-201, NCT04880031: A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

Active, not recruiting
2
231
US
Efimosfermin, BOS-580, Placebo
Boston Pharmaceuticals
Nonalcoholic Steatohepatitis (NASH)
11/25
11/25
NCT06920043: A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) MASH

Recruiting
2
42
US
Efimosfermin, BOS-580, Placebo
Boston Pharmaceuticals
Metabolic Dysfunction-Associated Steatohepatitis
11/27
11/27
AKP-11 / Akaal Pharma, Boston Pharma
ACTRN12617001223325: A Phase II Trial of Safety, Tolerability and Efficacy Study of Topical AKP-11 Administration to Participants with Arthritis.

Recruiting
2
100
 
Akaal Pharma PTY LTD, Akaal Pharma PTY LTD
arthritis treatment, osteoarthritis treatment, rheumatoid arthritis treatment, Gout treatment
 
 
ancremonam (BOS-228) / Boston Pharma
2017-003130-90: LYS228 PK, clinical response, safety and tolerability in patients with complicated intra-abdominal infection (cIAI)

Not yet recruiting
2
60
RoW, Europe
Piperacillin/tazobactam, Vancomycin (INN), Metronidazole (INN), Meropenem, LYS228, Powder for solution for infusion, Powder for concentrate for solution for infusion, Solution for infusion, Powder for solution for injection/infusion, Not specified; commercially available piperacillin/tazobactam; locally sourced, Not specified; commercially available vancomycin; locally sourced, Not specified; commercially available metronidazole; locally sourced, Not specified; commercially available meropenem; locally sourced
Novartis Pharma AG, Novartis Pharma AG
complicated Intra-Abdominal Infections (cIAI), complicated Intra-Abdominal Infections (cIAI), Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 

Download Options